|
|
| Oncologie > Etude de marché sectorielle |
|
|
|
|
€ 160,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Septembre 2006 |
Taille du document : |
30 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Stakeholder Opinions: Primary Brain Cancer - Temozolomide Turns Heads
144 pages | Juillet 2005 |
IntroductionThe incidence of glioblastoma is increasing.
Schering-Plough's temozolomide has gained approval as first line therapy for glioblastoma and has provided some survival benefit.
However |
3 040,00 €
|
| |
| |
Stakeholder Insight: Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
199 pages | Avril 2005 |
IntroductionAnthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer.
In recent days, however, agents such as Sanofi-Aventis's Taxotere and Astr |
9 120,00 €
|
| |
| |
The Eastern European Cancer Market Outlook to 2010
177 pages | Décembre 2005 |
The countries of the Eastern European region feature a range of diverse healthcare systems, but can be divided into two categories, those of the EU accession countries which feature the strongest pros |
2 443,75 €
|
| |
| |
Pipeline Insight: Hematological malignancies - Targeted treatments and immunotherapy infuse new blood
219 pages | Avril 2005 |
IntroductionGiven an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treat |
9 120,00 €
|
| |
| |
Commercial Insight Top 20 Cancer Therapeutics
197 pages | Juillet 2006 |
IntroductionThe Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015.
Cytotoxics currently constitute the majority, due t |
12 160,00 €
|
| |
| |
Commercial Insight: Antihormonal Therapies Aromatase Inhibitors Reinvigorate a Mature Market
122 pages | Juillet 2005 |
IntroductionThe antihormonal cancer therapy market is characterized by a mature nature and a relatively high level of saturation.
Despite this, growth will continue slowly at a CAGR of 0.9% during |
12 160,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Cancer Diagnostic Testing World Markets
245 pages | Janvier 2006 |
The purpose of this report is to describe the specific segment of the cancer diagnostics market called tumor marker testing.
It examines those clinical measurement devices, and their reagents and s |
2 800,00 €
|
| |
| |
Stakeholder Opinions: Chronic Leukemias - Curative Intent Raises the Bar
174 pages | Octobre 2005 |
IntroductionRecognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy.
I |
3 230,00 €
|
| |
| |
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the major current business issues and events, including R&D news, licensing deals, alliances and joint ventures, and regulatory decisions.
|
|
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the major current business issues and events, including R&D news, licensing deals, alliances and joint ventures, and regulatory decisions.
|
|
|
PPLSEN
|
|
|
|
|
